Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Emergent Biosolutions
(NY:
EBS
)
10.74
+2.08 (+24.02%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Emergent Biosolutions
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
May 10, 2021
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March...
Via
Benzinga
Exposures
Product Safety
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 10, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 07, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 06, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 05, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2021
May 05, 2021
Upgrades Atlantic Equities upgraded the previous rating for Under Armour Inc (NYSE:UAA) from Underweight to Neutral. Under Armour earned $0.16 in the first quarter. The...
Via
Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Why Emergent BioSolutions Stock Dropped 30% in April
May 04, 2021
The company went from hero to zero in the fight against COVID-19.
Via
The Motley Fool
Exposures
COVID-19
NYSE:EBS Investor Notice: Lawsuit Alleges Securities Laws Violations by Emergent BioSolutions Inc
May 04, 2021
San Diego, CA -- (SBWIRE) -- 05/04/2021 -- An investor, who purchased NYSE:EBS shares, filed a lawsuit against Emergent BioSolutions Inc over alleged violations of Federal Securities Laws.
Via
SBWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 04, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Is Emergent BioSolutions Still a Buy After Its Coronavirus Vaccine Flub?
May 04, 2021
Shareholders beware: The hits just won't stop coming.
Via
The Motley Fool
Exposures
COVID-19
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 03, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
SHAREHOLDER ALERT: Law Offices of Timothy L. Miles Announces Emergent BioSolutions Inc. (EBS) Sued by Shareholders
May 02, 2021
SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders
Via
EIN Presswire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
April 30, 2021
Emergent BioSolutions Inc has manufactured over 115 million doses of the drug substance used in the Johnson & Johnson COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at...
Via
Talk Markets
Exposures
COVID-19
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
April 30, 2021
Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19...
Via
Benzinga
Exposures
COVID-19
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 30, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
April 30, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days
April 30, 2021
Emergent BioSolutions Inc (NYSE: EBS) said it hopes to respond to U.S. regulators within days on how to resolve the problems at its Baltimore plant, which have forced...
Via
Benzinga
Exposures
Product Safety
EMERGENT INVESTORS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
April 30, 2021
From
Lieff Cabraser Heimann & Bernstein, LLP
Via
Business Wire
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
April 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...
Via
Benzinga
Emergent BioSolutions Inc (EBS) Q1 2021 Earnings Call Transcript
April 30, 2021
EBS earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Emergent BioSolutions: Q1 Earnings Insights
April 29, 2021
Shares of Emergent BioSolutions (NYSE:EBS) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15200.00% over the...
Via
Benzinga
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 29, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Emergent BioSolutions Inc. Investors of Class Action and Encourages Investors to Contact the Firm
April 29, 2021
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
EMERGENT SHAREHOLDERS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
April 29, 2021
From
Lieff Cabraser Heimann & Bernstein, LLP
Via
Business Wire
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 28, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
April 28, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
A Preview Of Emergent BioSolutions's Earnings
April 28, 2021
Emergent BioSolutions (NYSE:EBS) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings...
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.